ITU and Aging: A Single-Axiom View of Kₒrganism Decay, Three-Pillar Mechanisms, Interventions, and the 2026-2050 Roadmap

We apply the Information-Theoretic Unification (ITU) framework (Terada 2026, DOI 10. 5281/zenodo. 20109210) to aging biology. Aging is re-expressed as slow exponential decay of Kₒrganism over time - the chronic counterpart to cancer's acute K breakdown (Tier 1 #5, DOI 10. 5281/zenodo. 20174318). This is Tier 1 paper #6, advancing the ITU medicine triangle to 2/3 complete. Phase 63: ITU foundation. The Gompertz mortality law mu (t) = A*exp (alpha*t) is derived as a direct consequence of K (t) = K₀*exp (-beta*t). The 12 Hallmarks of Aging (Lopez-Otin 2023) are mapped to 12 K-component degradation modes; mean K-control loss reaches 53. 6% at age 80 vs 25. The Horvath DNA methylation clock is interpreted as a K-fidelity meter; Sinclair's information theory of aging finds its mathematical basis in ITU. Species lifespan-alpha product (mouse 2. 8, dog 3. 0, human 10. 4, bowhead 8. 4, lobster/hydra ~1) confirms ITU's L proportional to 1/alpha prediction. Phase 64: Three fundamental pillars - telomere attrition (Kᵣeplication), mitochondrial dysfunction (Kₑnergy), proteostasis loss (Kᵢnformationᵢntegrity). The Hayflick limit is reproduced at ~53 divisions. mtDNA heteroplasmy with clonal expansion gives 10. 5% of cells above 60% dysfunction threshold at age 80. Protein aggregate dynamics with prion-like amplification (C² term) produce APOE4-carrier disease onset at age 84. The composite K (age) shows positive feedback decay - aging accelerates because the three pillars mutually reinforce. Phase 65: Six longevity interventions evaluated on a unified K-component restoration matrix - rapamycin (Kₚroteostasis, +12% mouse lifespan), metformin (Kₑnergy, +5%), senolytics D+Q (Kᵢmmune via SASP removal, +25%), NAD+ boosters (Kₑnergy, +8%), caloric restriction (multi-K, +30%), OSKM partial reprogramming (Kᵢnformation +60%, +20% lifespan but TRL=2 with cancer risk). Combinations yield diminishing returns: Rapa+Met +15%, triple combo +35%, five-drug combo +52%. As in cancer (Tier 1 #5), multi-K simultaneous restoration is ITU-necessary. Phase 66: 2026-2050 longevity roadmap. Three lifespan scenarios: status quo (88 yr by 2050), ITU mid (95), ITU+OSKM optimistic (100). The healthspan-lifespan gap shrinks 10 -> 3 years. Longevity industry investment grows 5. 2B (2024) -> 120B (2050). Regulatory milestones: TAME trial results 2028, FDA biological-aging indication by 2030, OSKM in-human trial by 2030, multi-K combo insurance coverage by 2040, ICD-12 codes for 'biological aging' by 2040. Ten falsifiable predictions issued for 2026-2050. Central thesis: aging = chronic exponential decay of Kₒrganism; therapy requires multi-K simultaneous restoration over decades (vs cancer's acute multi-K restoration over months). Honest framing: this is a Pass-1 interpretive paper that reframes known gerontology (Hallmarks, Gompertz, Hayflick, Horvath, Sinclair theory, intervention pharmacology) in ITU language and matches established data but does not produce ITU-unique predictions. Pass-2 follow-up work would derive an ITU-specific longevity biomarker validated against long-term outcome data. This completes the second vertex of the ITU medicine triangle: Cancer (#5, acute K breakdown) + Aging (#6, chronic K decay). Tier 1 #7 (Psychiatry) is planned next. The engineering rectangle (Quantum Computing 10. 5281/zenodo. 20139391 + Machine Consciousness 10. 5281/zenodo. 20150501 + Cryptography 10. 5281/zenodo. 20151059 + Semiconductors 10. 5281/zenodo. 20174036) is now joined by a 2-vertex medicine vector. Includes 4 theory documents, 4 Python numerical experiments, 4 figures, 4 JSON summaries. Total runtime ~25 seconds.